Oral piretanide in chronic renal failure

Area of Science:

• Nephrology
• Clinical Pharmacology

Background:

• Severe chronic renal insufficiency significantly impairs the kidney's ability to excrete excess fluid and electrolytes.
• Diuretic agents like frusemide and bumetanide are commonly used, but efficacy can be limited in advanced renal disease.

Purpose of the Study:

• To evaluate the efficacy and effects of high-dose piretanide in patients with severe chronic renal insufficiency.
• To compare the diuretic and natriuretic response to piretanide with known responses to bumetanide and frusemide.

Main Methods:

• Twelve patients with creatinine clearance below 25 ml/min received either 30 mg or 60 mg of piretanide orally.
• Urine volume, electrolyte excretion, and excretion of creatinine, urea, and uric acid were measured over 24 hours post-administration.
• A water load was administered prior to piretanide dosing.

Main Results:

• Piretanide administration resulted in significant diuresis (increased urine volume).
• Piretanide demonstrated effective natriuresis (increased sodium excretion) in this patient cohort.
• The observed effects were comparable to those previously reported for bumetanide and frusemide.

Conclusions:

• High doses of piretanide are effective in promoting diuresis and natriuresis in patients with severe chronic renal insufficiency.
• Piretanide represents a viable therapeutic option for managing fluid and electrolyte balance in this patient population.
• Further studies may elucidate the precise role of piretanide relative to other loop diuretics in renal impairment.